• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity.每日经导管单剂量注射组织型纤溶酶原激活剂治疗急性下肢深静脉血栓形成
J Vasc Interv Radiol. 2001 Feb;12(2):247-52. doi: 10.1016/s1051-0443(07)61832-6.
2
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.在犬动静脉联合血栓形成模型中组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(u-PA)和K1K2Pu(一种t-PA/u-PA嵌合体)的溶栓特性比较
J Am Coll Cardiol. 1992 May;19(6):1350-9. doi: 10.1016/0735-1097(92)90344-m.
3
Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity.经皮导管接触溶栓术联合小剂量尿激酶持续输注治疗下肢非急性期深静脉血栓形成。
Korean J Radiol. 2011 Jan-Feb;12(1):97-106. doi: 10.3348/kjr.2011.12.1.97. Epub 2011 Jan 3.
4
Evaluation of thrombolysis using tissue plasminogen activator in lower extremity deep venous thrombosis with concomitant femoral-popliteal venous segment involvement.下肢深静脉血栓形成伴股腘静脉段受累患者应用组织型纤溶酶原激活物溶栓的评估。
J Vasc Surg Venous Lymphat Disord. 2017 Sep;5(5):613-620. doi: 10.1016/j.jvsv.2017.04.018. Epub 2017 Jun 21.
5
Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.使用尿激酶和重组组织型纤溶酶原激活剂进行导管定向外周动脉和静脉溶栓相关的并发症。
J Vasc Interv Radiol. 2000 Mar;11(3):295-8. doi: 10.1016/s1051-0443(07)61420-1.
6
Catheter-directed thrombolysis for the management of postpartum deep venous thrombosis.导管定向溶栓治疗产后深静脉血栓形成
Acta Obstet Gynecol Scand. 2005 Feb;84(2):155-8. doi: 10.1111/j.0001-6349.2005.00565.x.
7
Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.阿替普酶作为尿激酶的替代药物。导管定向溶栓治疗咨询小组。
J Vasc Interv Radiol. 2000 Mar;11(3):279-87. doi: 10.1016/s1051-0443(07)61418-3.
8
Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator.
J Vasc Interv Radiol. 1996 Nov-Dec;7(6):845-51. doi: 10.1016/s1051-0443(96)70858-8.
9
Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulation--results of pilot study.下肢深静脉血栓形成:每日一次阿替普酶直接注入血栓并联合全身抗凝治疗——初步研究结果
Radiology. 2008 Feb;246(2):619-29. doi: 10.1148/radiol.2461062076.
10
Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA).
Eur J Vasc Endovasc Surg. 1996 Jul;12(1):97-104. doi: 10.1016/s1078-5884(96)80283-8.

引用本文的文献

1
Vortex-ultrasound for microbubble-mediated thrombolysis of retracted clots.用于回缩性血栓微泡介导溶栓的涡旋超声
Appl Phys Lett. 2023 Aug 14;123(7):073701. doi: 10.1063/5.0155223. Epub 2023 Aug 16.
2
Safety and Efficacy of Catheter Direct Thrombolysis in Management of Acute Iliofemoral Deep Vein Thrombosis: A Systematic Review.导管直接溶栓治疗急性髂股深静脉血栓形成的安全性和有效性:一项系统评价
Vasc Specialist Int. 2017 Dec;33(4):121-134. doi: 10.5758/vsi.2017.33.4.121. Epub 2017 Dec 31.
3
Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation.采用低剂量局部注射重组组织型纤溶酶原激活物和区域性抗凝治疗高危静脉血栓患者。
J Vasc Interv Radiol. 2013 Jan;24(1):27-34.e1. doi: 10.1016/j.jvir.2012.09.017.
4
Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis.低剂量、每日一次、腔内注射重组组织型纤溶酶原激活剂治疗急性下肢深静脉血栓形成。
J Vasc Interv Radiol. 2011 Aug;22(8):1107-16. doi: 10.1016/j.jvir.2011.03.023. Epub 2011 Jun 12.
5
Epidural hematoma mimicking transverse myelitis in a patient with primary antiphospholipid syndrome.
Rheumatol Int. 2008 May;28(7):709-12. doi: 10.1007/s00296-007-0512-5. Epub 2007 Dec 12.
6
Temporary Vena Caval Interruption and Thrombolysis in the Management of Deep Vein Thrombosis.临时腔静脉阻断与溶栓治疗在深静脉血栓形成管理中的应用
Curr Treat Options Cardiovasc Med. 2005 Jun;7(2):149-158. doi: 10.1007/s11936-005-0016-0.

本文引用的文献

1
The anatomy of deep venous thrombosis of the lower extremity.下肢深静脉血栓形成的解剖学
J Vasc Surg. 2000 May;31(5):895-900. doi: 10.1067/mva.2000.105956.
2
Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.使用组织纤溶酶原激活剂增强实验性脉冲喷雾溶栓,可使剂量降低一个或多个数量级。
J Vasc Interv Radiol. 2000 Mar;11(3):299-303. doi: 10.1016/s1051-0443(07)61421-3.
3
Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities.
Am J Med. 2000 Feb 15;108(3):251-5. doi: 10.1016/s0002-9343(99)00407-6.
4
Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry.导管定向溶栓治疗下肢深静脉血栓形成:一项全国多中心注册研究报告
Radiology. 1999 Apr;211(1):39-49. doi: 10.1148/radiology.211.1.r99ap4739.
5
Venous thrombosis as a chronic disease.静脉血栓形成作为一种慢性疾病。
N Engl J Med. 1999 Mar 25;340(12):955-6. doi: 10.1056/NEJM199903253401209.
6
Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy.
J Vasc Interv Radiol. 1997 May-Jun;8(3):405-18. doi: 10.1016/s1051-0443(97)70581-5.
7
Lower extremity deep venous thrombolysis: a new approach to obtaining access.
J Vasc Interv Radiol. 1996 Mar-Apr;7(2):283-8. doi: 10.1016/s1051-0443(96)70781-9.
8
Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator.
J Vasc Interv Radiol. 1996 Nov-Dec;7(6):845-51. doi: 10.1016/s1051-0443(96)70858-8.
9
The long-term clinical course of acute deep venous thrombosis.急性深静脉血栓形成的长期临床病程。
Ann Intern Med. 1996 Jul 1;125(1):1-7. doi: 10.7326/0003-4819-125-1-199607010-00001.
10
Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis.髂股深静脉血栓形成:导管定向溶栓的积极治疗
Radiology. 1994 May;191(2):487-94. doi: 10.1148/radiology.191.2.8153327.

每日经导管单剂量注射组织型纤溶酶原激活剂治疗急性下肢深静脉血栓形成

Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity.

作者信息

Chang R, Cannon R O, Chen C C, Doppman J L, Shawker T H, Mayo D J, Wood B, Horne M K

机构信息

Department of Diagnostic Radiology, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Vasc Interv Radiol. 2001 Feb;12(2):247-52. doi: 10.1016/s1051-0443(07)61832-6.

DOI:10.1016/s1051-0443(07)61832-6
PMID:11265890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2374747/
Abstract

The strong fibrin affinity of recombinant tissue plasminogen activator (rt-PA) theoretically obviates continuous infusion or replacement of t-PA after direct intrathrombic injection. This hypothesis led the authors to evaluate single daily catheter-directed injection of rt-PA as a thrombolytic treatment for acute deep vein thrombosis of the lower extremity. Once-daily injection of rt-PA was performed in large thrombosed veins (popliteal or larger) with use of pulse-spray catheters and in small thrombosed veins in patients' calves with use of 3-4-F coaxial catheters. Patients received only full systemic anticoagulation on his/her patient care unit. This dosing regimen has been tested in 10 patients (12 legs) with a maximum dose of 50 mg per leg per day. Extensive thrombolysis was achieved in nine patients and partial thrombolysis was achieved in one patient, at an average total dose of 106 mg of rt-PA per leg. Minor bleeding was seen in three patients and no transfusions were needed. Our technique and the rationale for this pilot study is the focus of this article.

摘要

重组组织型纤溶酶原激活剂(rt-PA)对纤维蛋白具有很强的亲和力,从理论上讲,在直接血栓内注射后无需持续输注或补充t-PA。这一假设促使作者评估每日单次导管定向注射rt-PA作为下肢急性深静脉血栓形成的溶栓治疗方法。使用脉冲喷射导管对大的血栓形成静脉(腘静脉或更大的静脉)以及使用3-4F同轴导管对患者小腿的小血栓形成静脉进行rt-PA每日一次注射。患者仅在其病房接受充分的全身抗凝治疗。该给药方案已在10例患者(12条腿)中进行了测试,每条腿每天的最大剂量为50 mg。9例患者实现了广泛溶栓,1例患者实现了部分溶栓,每条腿rt-PA的平均总剂量为106 mg。3例患者出现轻微出血,无需输血。本文重点介绍我们的技术以及这项初步研究的基本原理。